Thermo Fisher Scientific priced $3.8 billion of senior notes across maturities to help fund its pending $8.8 billion acquisition of clinical trial data platform provider Clario Holdings. The debt package spans 2031–2046 maturities and will close ahead of the acquisition, with proceeds also earmarked for general corporate purposes. The financing signals Thermo Fisher’s continued drive to bolster its clinical‑software and trial services capabilities while using the capital markets to bridge M&A costs. Investors will watch integration plans and how the Clario buy complements Thermo Fisher’s lab and trial operations franchises.